WPD Pharmaceuticals Inc. announced that it was informed that the Polish National Center for Research and Development ("NCRD") has signed an agreement with WPD for a grant of CAD 6.3million (PLN 20,394,049.68) for the development of Liposomal Annamycin for the treatment of Acute Myeloid Leukemia. The grant signing resulted from the Company receiving a positive evaluation of its application submitted under the 6/1.1.1/2020 - Fast track competition for a grant (POIR.01.01.01-00-1913/20) from the Polish National Center for Research and Development. The funds will be used for the continued development of Annamycin and is expected to cover about 60% of the research activities planned for grant-funded project leading to further development of Annamycin in leukemia. The the project is intended to develop a new combination of drugs and clinical verification of its effectiveness in AML therapy. The project entitled: "Innovative approach to the treatment of acute myeloid leukemia (AML)" will be co-financed by the European Union, from the European Regional Development Fund, under the Smart Growth Operational Program 2014-2020. The NCRD is an executive agency of the Polish Minister of Science and Higher Education. It was established as a unit to implement tasks in the field of science, technology and state innovation policy. The chief aim of the centre is to support the creation of innovative solutions and technologies that increase the competitiveness and innovation of the Polish economy.